Moreover, NSCLC patients with a high T790M/activating EGFR-mutation ratio in tumor samples or in plasma cfDNA have displayed a significantly better RR to second-line osimertinib and a longer PFS than patients with a low ratio [268,269]. This evidence concerns the gene EGFR and neoplasm.